CI

At a glance

ClinicalIndex Comparison Record
Phase 4Not Yet Recruiting· 472 target
Drug / intervention
Aspirin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05910125
NCT05910125Phase 4Not Yet Recruiting
CompareCT.gov

Aspirin Combined With Clopidogrel Versus Intravenous Alteplase for Acute Minor Stroke: An Open-label, Blinded Endpoint, Randomized Controlled Trial

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University·interventional·Posted Jun 18, 2023·Updated Jun 18, 2023

In Brief

A Phase 4 clinical trial evaluating Aspirin, Clopidogrel, and 1 other intervention for Ischemic Stroke. Not yet recruiting, targeting 472 participants across 1 site.

Detailed Summary

An open-label, blinded endpoint, randomized controlled trial that includes patients diagnosed with non-disabling, non-large vessel occlusion, acute minor stroke within 4.5 hours of onset. Eligible participants would be randomly assigned to the thrombolysis group (intravenous alteplase) and the dual antiplatelet group (oral aspirin plus clopidogrel). The primary outcome is the proportion of the excellent functional outcome (modified Rankin scale 0-1) at 90 days.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIschemic Stroke
CountriesChina
Collaborators--

Timeline

Phase 4Not Yet Recruiting
2024202520262027
First PostedJun 18, 2023
Enrollment StartJul 1, 2023
Primary CompletionJul 1, 2027
TodayJul 1, 2026
Enrollment to primary: 4 yearsPosted 3.0 years agoPrimary completion in 1 year

Interventions

Aspirindrug

See arm/group descriptions.

Clopidogreldrug

See arm/group descriptions.

Alteplasedrug

See arm/group descriptions.